Anemia of CKD
Physiologic Regulation of EPO Production for CKD Anemia: An Opportunity to Enhance Access to Care
Speakers: David Wheeler, MD, Professor of Kidney MedicineLynda Szczech, MD, MSCE, NephrologistMatthew Weir, MD, Director of the Division of Nephrology, Department of Medicine
Duration: 60 minutes
Presented on: December 21, 2022
David Wheeler, MD
David Wheeler, MD
Professor of Kidney MedicineDavid Wheeler, MD, is Professor of Kidney Medicine at University College London and Honorary Consultant Nephrologist at the Royal Free London NHS Foundation Trust. He is a clinical scientist interested in chronic kidney disease (CKD). Dr. Wheeler has participated in the development and delivery of several large-scale clinical trials testing lipid lowering regimens (SHARP), calcimimetics (EVOLVE), intravenous iron (PIVOTAL), SGLT2 inhibitors (CREDENCE and DAPA-CKD) and HIF stabilisers (ASCEND) in patients with CKD. He was co-chief investigator for the DAPA-CKD study. Moreover, Dr. Wheeler has been involved in the development of Clinical Practice Guidelines for several organizations like KDIGO. In the UK, he is National Institute of Health Research (NIHR) Specialty Lead for Renal Disorders.
Lynda Szczech, MD, MSCE
Lynda Szczech, MD, MSCE
NephrologistLynda Szczech, MD, MSCE, is a nephrologist, trained in Internal Medicine at Duke University and Nephrology at the University of Pennsylvania. After graduation, she was on faculty at Duke University conducting multicenter clinical trials in nephrology and cardiovascular disease. During that time, Dr. Szczech authored papers exploring relationships in multiple areas to include HIV-related kidney disease, health outcomes research, and cardiovascular disease in people with kidney disease. Following this, she designed clinical development programs for companies with drugs and devices for patients with kidney disease, worked with regulatory agencies to develop programs capable of achieving approval, and developed global medical affairs departments to share information on these clinical trials.
Matthew Weir, MD
Matthew Weir, MD
Director of the Division of Nephrology, Department of MedicineMatthew Weir, MD, is attending physician and Director of the Division of Nephrology in the Department of Medicine at the University of Maryland Hospital, Baltimore. He is also Professor of Medicine at the University of Maryland School of Medicine. Dr. Weir’s primary research interests include the use of antihypertensive therapy for the treatment of diabetic nephropathy, hypertensive renal injury in African Americans, cardiovascular disease in patients with chronic kidney disease, and mineralocorticoid receptor antagonism to treat atherosclerosis. In addition, he is a member of numerous associations, including the American Society of Nephrology and the National Kidney Foundation. Dr. Weir reviews manuscripts for over 30 major medical journals, including the American Society of Nephrology.
CME InformationPhysiologic Regulation of EPO Production for CKD-Anemia: An Opportunity to Enhance Access to CareThis activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the Kidney Disease: Impacting Global Outcomes (KDIGO).
ACKNOWLEDGEMENTThis educational activity is supported by an educational grant from GSK.
DATE OF RELEASE/EXPIRATIONThis activity was released on December 21, 2022 and is valid for 12 months. Requests for credit must be made no later than December 21, 2023.
TARGET AUDIENCEThe educational design of this activity addresses the needs of nephrologists, dialysis center medical directors, hospitalists, hematologists, and specialty NPs and PAs. Secondary audiences include primary care clinicians, internal medicine specialists, cardiologists, endocrinologists, family medicine and/or allied NPs and PAs.
STATEMENT OF NEED/PROGRAM OVERVIEWAnemia in chronic kidney disease (CKD) is often under-recognized and undertreated, leaving patients to live with a significant health burden. Further, patients from certain racial and ethnic groups disproportionately suffer from poor screening rates and a lack of appropriate management of their anemia. Emerging agents for the management of anemia in CKD target a novel physiologic pathway and, if approved, could provide additional options to relieve the burden associated with anemia in CKD.
Join a panel of expert nephrologists and patient advocates to explore the current treatment landscape for anemia in CKD, including iron supplementation and use of erythropoiesis-stimulating agents. Panelists will review emerging agents, investigational hypoxia-inducible factor prolyl hydroxylase inhibitors, including their mechanism of action, efficacy, and safety. Clinicians will also discover strategies to improve access to anemia care for under-resourced and diverse patient populations.
EDUCATIONAL OBJECTIVESAfter completing this activity, the participant should be better able to:
- Describe the personal and societal burden of anemia and its care on patients with CKD, including those undergoing dialysis
- Discuss strategies to enhance access to anemia care for racial groups, such as Black patients, to ensure they receive proper and timely diagnoses and management
- Summarize the role of hypoxia-inducible factor in the production of EPO
- Summarize experience data with hypoxia-inducible factor prolyl hydroxylase inhibitors in increasing Hb levels compared to standard of care in both dialysis-dependent patients and patients not receiving dialysis
PHYSICIAN ACCREDITATION STATEMENTThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.
PHYSICIAN CREDIT DESIGNATIONGlobal Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ESTIMATED TIME TO COMPLETEThis activity should take approximately 1 hour to complete.
INSTRUCTIONS TO RECEIVE CREDITIn order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.
HARDWARE/SOFTWARE REQUIREMENTSParticipants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
FEE INFORMATION & REFUND/CANCELLATION POLICYThere is no fee for this educational activity.
DISCLOSURE OF CONFLICTS OF INTERESTGlobal Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Name of Faculty or Presenter Reported Financial Relationship Lynda Szczech, MD, MSCE
Consulting Fee (e.g., Advisory Board): CeleCor
Stock Shareholder: FibroGen
David C. Wheeler, MD
Professor of Kidney Medicine
University College London
Consulting Fee (e.g., Advisory Board): Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, GlaxoSmithKline, Tricida
Contracted Research: AstraZeneca
Honoraria: Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Gilead, GlaxoSmithKline, Janssen, Merck Sharp and Dohme, Mundipharma, Tricida, Vifor, Zydus
Speakers' Bureau: Amgen, Astellas, AstraZeneca
Matthew R. Weir, MD
Professor and Chief
Division of Nephrology
University of Maryland School of Medicine
Consulting Fee (e.g., Advisory Board): Akebia, AstraZeneca, Bayer, Boehringer Ingelheim, Glaxo, Janssen, NovoNordisk, Vifor
The planners and managers have the following relevant financial relationships with ineligible companies:
Name of Planner Reported Financial Relationship Lindsay Borvansky Nothing to disclose Andrea Funk Nothing to disclose Liddy Knight Nothing to disclose Ashley Cann Nothing to disclose Lauren Sinclair Nothing to disclose Jaimee Harris-Gold Nothing to disclose Terry Glauser Nothing to disclose
DISCLOSURE OF UNLABELED USEThis educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER:Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Accreditation Support:For information about the accreditation of this program, please contact Global at 303-395-1782 or email@example.com
Technical Support:For any technical issues or issues with your CME Certificate, please contact ClinicalSeriesLive at 877-394-1306 or at Support@ClinicalSeriesLive.com.